Clinical trial
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic…
NCT00006010 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00006010 |
|---|---|
| Title | Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer |
| Official title | Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, gemcitabine hydrochloride |
| Enrollment | 25 |
| Start date | Sep 1, 2001 |
| Primary completion | May 1, 2004 |
| Completion | Apr 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: